FDA Agrees to Change Endpoint; Aerie Pharmaceuticals Analyst Update - BrokerBank Securities
Jun 17, 2015, 07:00 ET
NEW YORK, June 17, 2015 /PRNewswire/ -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) gained more than 50% yesterday and have more than doubled since our initial buy recommendation on April 30, 2015. The company received positive feedback from the FDA which allowed the company to modify the endpoints of their Rocket 2 trial based on analysis of their Rocket 1 results.
An analyst report updates our view on AERI that includes a brief company overview, current pipeline, financial review, analyst summary, valuation, and recommendation can be viewed by using the following link at no cost.
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael McCord, CFA charterholder. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute
SOURCE BrokerBank Securities, Inc.
Share this article